60 Degrees Pharmaceuticals, Inc. filed a Form 8-K on November 6, 2026, disclosing inducement offer letter agreements dated November 5, 2026, under which holders of existing warrants agreed to exercise for cash at a reduced price of $0.90 per share in exchange for new unregistered warrants covering twice the number of shares.

Key Highlights

  • Reduced exercise price: Existing warrants covering 584,492 shares of common stock, originally issued at prices ranging from $7.60 to $27.60 per share, were repriced to $0.90 per share under the inducement letters.
  • Expected gross proceeds: The company disclosed it expects to receive aggregate gross proceeds of $526,042.80 from the exercise of the existing warrants, before placement agent fees and other offering expenses.
  • New warrants issued: The company agreed to issue new unregistered warrants to purchase up to 1,168,984 shares of common stock, representing 200% of the existing warrant shares exercised.
  • Closing expected: The closing of the transactions is expected to occur on or about November 9, 2026, subject to customary closing conditions.
  • Stockholder approval required: The new warrants may not be exercised prior to the date stockholder approval is received, and the company agreed to hold a stockholder meeting within 90 days of the inducement letters.
  • Placement agent fees: H.C. Wainwright and Co., LLC will receive a cash fee of 7.5% of gross proceeds, a management fee of 1.0% of gross proceeds, $10,000 for non-accountable expenses, and warrants to purchase up to 43,837 shares at $1.125 per share.

60 Degrees Pharmaceuticals Enters Warrant Inducement Agreements on November 5, 2026

According to the filing, 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) entered into inducement offer letter agreements with certain holders of existing warrants originally issued on September 5, 2024, January 30, 2025, February 6, 2025, and July 16, 2025, at exercise prices of $27.60, $15.42, $11.80, and $7.60 per share, respectively. Under the agreements, those holders agreed to exercise their warrants for cash at a reduced price of $0.90 per share, covering an aggregate of 584,492 shares of common stock, par value $0.0001 per share.

In exchange, the company agreed to issue new unregistered warrants to purchase up to an aggregate of 1,168,984 shares of common stock, equal to 200% of the exercised shares. The new warrants carry an exercise price of $0.90 per share and are split into two tranches: warrants to purchase up to 560,912 shares expiring on the five-year anniversary of the later of the stockholder approval date or the effective date of a resale registration statement, and warrants to purchase up to 608,072 shares expiring on the twenty-four-month anniversary of the same date. The filing noted that holders are subject to a 4.99% beneficial ownership cap (or up to 9.99% at the holder's election) on exercise. Under certain fundamental transactions, the filing disclosed, holders may require the company to purchase unexercised warrants at their Black Scholes Value.

The company disclosed it intends to use net proceeds for working capital and general corporate purposes. It also agreed to file a resale registration statement for the new warrant shares within 30 calendar days of the inducement letters and to use commercially reasonable efforts to have it declared effective within 60 calendar days (or 90 calendar days in the case of a full SEC review). The new warrants and placement agent warrants are being offered in reliance on the exemption provided by Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D, according to the filing.

What Was Disclosed

The company disclosed inducement offer letter agreements repricing existing warrants on 584,492 shares to $0.90, expected gross proceeds of $526,042.80, issuance of 1,168,984 new unregistered warrants at $0.90 per share, placement agent compensation terms, and registration and stockholder approval obligations.